References
- Yamasaki K., Kanbe T., Chijiwa T., Ishiyama H., Morita S. Gastric mucosal protection by OPC‐12759, a novel antiulcer compound, in the rat. Eur. J. Pharmacol. 1987; 142: 23–30, [PUBMED], [INFOTRIEVE]
- Yamasaki K., Ishihara H., Imaizumi T., Kabe T., Yabuuchi Y. Effect of OPC‐12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer and gastric secretion in rats. Jpn. J. Pharmacol. 1989; 49: 441–448, [PUBMED], [INFOTRIEVE], [CSA]
- Arakawa T., Kobayashi K., Yoshikawa T., Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig. Dis. Sci. 1998; 43: 5S–13S, [PUBMED], [INFOTRIEVE], [CSA]
- Ishihara K., Komuro Y., Nishiyama N., Yamasaki K., Hotta K. Effect of rebamipide on mucus secretion by endogenous prostaglandin‐independent mechanism in rat gastric mucosa. Arzneim.‐Forsch./Drug Res. 1992; 42: 1462–1466, [CSA]
- Mizoguchi H., Ogawa Y., Kanatsu K., Tanaka A., Kato S., Takeuchi K. Protective effect of rebamipide on indomethacin‐induced intestinal damage in rats. J. Gastroenterol. Hepatol. 2001; 16: 1112–1119, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Udagawa A., Shiota G., Ichiba M., Murakawa Y. Effect of rebamipide on acetic acid‐induced gastric ulcer in rats: involvement of hepatic growth factor. Scand. J. Gastroenterol. 2003; 38: 141–146, [PUBMED], [INFOTRIEVE]
- Kishimoto S., Haruma K., Tari A., Sakurai K., Nakano M., Nakagawa Y. Rebamipide, an anti‐ulcer drug, prevents DSS‐induced colitis formation in rats. Dig. Dis. Sci. 2000; 45: 1608–1616, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Miyake M., Oka Y., Minami T., Toguchi H., Odomi M., Ogawara K., Higaki K., Kimura T. Combinatorial use of sodium laurate with taurine or L‐glutamine enhances colonic absorption of rebamipide, poorly absorbable antiulcer drug, without any serious histopathological mucosal damages. J. Pharm. Sci. 2003; 92: 911–921, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Shioya Y., Kashiyama E., Okada K., Kusumoto N., Abe Y., Uchida M., Shimizu T. Metabolic fate of the anti‐ulcer agent, (±)‐2‐(4‐chlorobenzoylamino)‐3‐[2(1 H)quinolinon‐4‐yl]propionic acid (OPC‐1759): absorption, distribution, and excretion in rats and dogs. Iyakuhin Kkenkyu 1989; 20: 522–533
- Fix J. A. Absorption enhancing agents for the GI system. J. Control. Release 1987; 6: 151–156, [CROSSREF]
- Lindmark T., Kimura Y., Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco‐2 cells. J. Pharmacol. Exp. Ther. 1998; 284: 362–369, [PUBMED], [INFOTRIEVE], [CSA]
- Morris K. R., Fakes M. G., Thakur A. B., Singh A. W., Venit J. J. An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm. 1994; 105: 209–217, [CROSSREF]
- Engel G. L., Farid N. A., Faul M. M., Richardson L. A., Winneroski L. L. Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm. 2000; 198: 239–247, [PUBMED], [INFOTRIEVE], [CROSSREF]
- O'Connor K. M., Corrigan O. I. Comparison of the physicochemical properties of the N‐(2‐hydroxyethyl) pyrrolidine, diethylamine and sodium salt forms of diclofenac. Int. J. Pharm. 2001; 222: 281–293, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rho J. I. A New Rebamipide Lysinate, Rebamipide Argininate and Pharmaceutical Preparation Containing the Same as Active Substance. Korea Patent 10 2003 0035382, June 2, 2003
- Naito Y., Yoshikawa T., Iinuma S., Miyazaki R., Yagi N., Yoshida N., Osumi T., Hirao Y., Kondo M. Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. Arzneim.‐Forsch./Drug Res. 1996; 46: 698–700
- Shioya Y., Shimizu T. High‐performance liquid chromatographic procedure for the determination of a new anti‐gastric agent, 2‐(4‐chlorobenzoylamino)‐3‐[2(1 H)quinolinon‐4‐yl]propionic acid, in human plasma and urine. J. Chromatogr. 1988; 434: 283–287, [PUBMED], [INFOTRIEVE]
- Zhao R., Duan J., Yan B. Determination of rebamipide in plasma by HPLC and its pharmacokinetic study. Zhongguo Yaoxue Zaxhi (Beizing) 1999; 34: 396–399
- Jamuludin A., Mohamad M., Navartnam V., Selliah K., Tan S. C. Relative bioavailability of the hydrochloride, sulfate, and ethyl carbonate salts of quinine. Br. J. Clin. Pharmacol. 1988; 25: 262–263
- Walmsley L. M., Taylor T., Wilkinson P. A., Brodie R. R., Chasseaud L. F., Alun‐Jones V. Plasma concentrations and relative bioavailability of naftidrofuryl from different salt forms. Biopharm. Drug Dispos. 1986; 7: 327–334, [PUBMED], [INFOTRIEVE]
- Akamatsu T., Nakamura N., Furuya N., Shimizu T., Gotou A., Kiyosawa K., Katsuyama T., Osumi T., Hirao Y., Miyamoto G. Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers. Dig. Dis. Sci. 2002; 47: 1399–1404, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]